— Know what they know.
/
Not Investment Advice

DVA

NYSE · USD
DaVita Inc.
Healthcare · Medical - Care Facilities
CEO Javier J. Rodriguez Employees 78,000 R&D / revenue 0.0%
Last price
$187.31−0.98%last session
Market cap
$12.0B
P/E (TTM)
16.1x
From 52w high
−24.3%
From 52w low
+85.5%
1-year return
+49.5%
RSI 14 · vs SMA200
57.6 · +8.0%
IS score
44.4/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

DVA   SPY   XLV (sector ETF) · weekly closes
80100120140160180200Jan 26Apr 26Jul 26Oct 26DVA 150XLV 124SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
30
Profitability
56
Growth
51
Value
75
Momentum
30
Risk (safety)
64
Quality
27
Balance sheet
63
Earnings quality

Flags

Strengths
✓ Piotroski 8+✓ FCF yield 5%+✓ Congress buying
Warnings
None of the computed warning flags fires for DVA (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Weak, Cost AdvantagePiotroski 8 / 9Altman Z 1.8Beta 0.832 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
0
11 open-market sales, $254.4M
Form 144 notices (12m): 8, $34.9M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
1
Last disclosed purchase 2026-03-27
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+49
123 new holders, 66 closed
630 filers hold 91.7% · 187 added, 224 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+156
537 funds adding shares
381 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
62.3%
20-day avg 71.8%, 50-day avg 73.2%
Latest 9.5 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$13.6B
Revenue growth YoY+6.5%
Gross margin27.0%
Operating income$2.0B
Operating margin14.7%
Net income$746.8M
Net margin5.5%
EPS (diluted)$9.51
Cash flow
Operating cash flow$1.9B
Capital expenditure$575.9M
Free cash flow$1.3B
FCF conversion (FCF / OCF)69.5%
Stock-based compensation$140.0M
FCF less SBC$1.2B
Buybacks$1.8B
Dividends$0
Balance sheet & returns
Cash & short-term investments$782.0M
Total debt$12.4B
Net debt$11.7B
Shareholders' equity$1.2B
Goodwill & intangibles$7.8B
Debt / equity-14.09
ROE (TTM)-123.6%
ROIC (TTM)11.2%
Operating margin by fiscal year
15.5%FY202111.5%FY202213.2%FY202316.3%FY202414.9%FY2025
Revenue $11.6B (FY2021) to $13.6B (FY2025), a 4.1% CAGR.

Valuation

P/E (TTM)16.1x
EV / EBITDA8.0x
Price / sales0.85x
Price / FCF7.4x
FCF yield13.47%
Buyback yield15.00%
SBC / revenue0.9%
Price / bookn/m
Forward P/E FY202612.6x
Forward P/E FY202711.0x
Forward P/E FY20289.6x
Forward multiples divide today's price by Street EPS estimates. Street mean target $228.80 across 5 analysts last quarter is theirs, not ours.

DVA vs industry median

157 companies in Medical - Care Facilities
Gross margin 31.0% 29.6% Operating margin 15.1% 2.4% Net margin 6.0% 1.2% ROIC 11.2% 5.6%
DVA (TTM)Industry median Asset turnover 0.79 vs industry 0.88 · financial leverage -23.15

Earnings delivery

Next report 2026-10-28 · consensus EPS $3.57
75%
beat rate, 9 of 12 quarters
+4.1%
median EPS surprise
3
longest beat streak
+30+2+16-2-5+5+3+9-21+5+19+4
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-07 to 2026-08-04. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
DVA DaVita Inc. $12.0B16.1x-123.6%6.0%+6.5% +49.5%
EHC Encompass Health Corporation $12.6B20.6x25.5%9.6%+9.5% +4.0%
UHS Universal Health Services, I $10.9B7.5x21.0%7.7%+10.0% −9.3%
ENSG The Ensign Group, Inc. $10.3B26.9x17.0%6.9%+18.9% −1.6%
PACS PACS Group, Inc. $7.4B27.6x28.1%5.3%+15.2% +276.9%
CHE Chemed Corporation $6.7B25.7x27.1%10.1%+3.3% —
THC Tenet Healthcare Corporation $21.5B10.2x53.3%14.7%+5.4% —
HIMS Hims & Hers Health, Inc. $6.3Bn/m-32.0%-11.5%+28.0% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-08-04Earnings Release; Exhibits
2026-06-08Material Agreement; Financial Obligation; Shareholder Vote; Exhibits
2026-05-05Earnings Release; Exhibits
2026-02-02Results of Operations and Financial Condition; Financial Statements and Exhibits
2025-11-25Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Statements and Exhibits
2025-10-29Results of Operations and Financial Condition; Financial Statements and Exhibits

Context

Shares outstanding63,800,000
Free float97.9%
Institutional ownership91.7%
Beta0.83
Dividend yield0.00%
Last dividendNone on file
50 / 200-day average$180.35 / $173.00
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Weak).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where DVA sits among 33 scored companies in Medical - Care Facilities (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureDVAIndustry medianIndustry percentileSector median
P/E (TTM) 14.1x 21.1x
30th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) 0.38 0.89
23rd		 1.28
Price / sales 0.9x 1.2x
34th		 3.7x
Price / book —
Price / tangible book —
Price / free cash flow 7.4x 15.2x
15th		 21.2x
Price / operating cash flow 5.4x 11.9x
17th		 17.1x
Enterprise value $22.0B $3.6B
94th		 $2.5B
EV / sales 1.6x 1.6x
50th		 3.8x
EV / EBITDA 8.0x 12.3x
25th		 16.2x
EV / EBIT 10.7x 14.6x
30th		 23.0x
EV / free cash flow 13.7x 21.4x
26th		 24.6x
Earnings yield 7.1% 4.0%
78th		 -0.3%
FCF yield 13.5% 5.3%
88th		 1.7%
Operating cash flow yield 18.4% 7.5%
84th		 2.9%
Graham number (per share) —

Profitability (TTM)

MeasureDVAIndustry medianIndustry percentileSector median
Gross margin 31.0% 27.8%
66th		 65.1%
EBITDA margin 19.7% 11.3%
78th		 6.6%
Operating margin 15.1% 8.0%
84th		 3.5%
EBIT margin 14.7% 7.7%
78th		 2.4%
Net margin 6.0% 4.8%
56th		 0.3%
NOPAT margin 11.9% 6.1%
81st		 2.7%
FCF margin 11.5% 6.7%
78th		 4.3%
Operating cash flow margin 15.7% 10.3%
88th		 7.1%
R&D / revenue 0.0% 0.0%
0th		 12.4%
SG&A / revenue 12.4% 15.5%
41st		 37.9%
Stock comp / revenue 0.9% 0.8%
60th		 4.5%
Effective tax rate 20.7% 21.9%
23rd		 21.0%

Returns on capital

MeasureDVAIndustry medianIndustry percentileSector median
ROE (on average equity) —
ROA 4.8% 6.2%
44th		 -0.3%
ROIC 17.9% 10.3%
75th		 5.5%
ROCE 13.8% 12.4%
56th		 2.3%
Return on tangible assets 11.7% 10.5%
56th		 1.7%
Cash ROIC (OCF / invested capital) 23.5% 15.0%
66th		 9.7%
Gross profitability (GP / assets) 24.5% 31.1%
47th		 29.9%
ROIC, 3-yr average 9.8% 4.7%
75th		 2.6%
ROIC, 5-yr average —
ROE, 5-yr average —
Incremental ROIC -41.6% 76.6%
13th		 17.2%

Growth

MeasureDVAIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 6.4% 10.0%
34th		 10.5%
Revenue growth (QoQ) 4.1% 4.0%
53rd		 7.2%
Revenue CAGR, 3 yr 6.1% 11.3%
21st		 10.7%
Revenue CAGR, 5 yr 3.9% 10.8%
19th		 12.1%
Gross profit CAGR, 3 yr 8.0% 12.7%
36th		 10.6%
Operating income CAGR, 3 yr 18.0% 12.3%
68th		 11.7%
Net income growth (TTM YoY) 1.3% 21.0%
17th		 17.5%
Net income CAGR, 3 yr 21.9% 23.5%
47th		 11.3%
EPS growth (TTM YoY) 18.6% 26.0%
33rd		 19.2%
EPS CAGR, 3 yr 36.8% 22.5%
73rd		 14.0%
EPS CAGR, 5 yr 10.6% 14.1%
43rd		 8.1%
FCF growth (TTM YoY) 24.9% 43.8%
38th		 18.6%
FCF CAGR, 3 yr 5.9% 22.1%
24th		 15.4%
Operating cash flow CAGR, 3 yr 3.7% 18.9%
17th		 11.9%
Book value CAGR, 3 yr —
Dividend CAGR, 3 yr —
Sustainable growth rate —

Margin history & stability

MeasureDVAIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 32.1% 30.0%
59th		 62.6%
Operating margin, 3-yr average 15.3% 6.6%
90th		 1.0%
Net margin, 3-yr average 6.4% 2.1%
72nd		 -2.6%
FCF margin, 3-yr average 10.5% 5.9%
93rd		 3.2%
Revenue stability (0-1) 0.88 0.92
38th		 0.80
Earnings stability (0-1) 0.01 0.33
10th		 0.37
Margin stability (0-1) 0.96 0.89
83rd		 0.93

Liquidity (latest quarter)

MeasureDVAIndustry medianIndustry percentileSector median
Cash & short-term investments $688.9M $185.6M
88th		 $330.9M
Net cash (− = net debt) −$10.1B −$705.2M
6th		 $8.4M
Working capital $1.3B $116.0M
97th		 $381.1M
Current ratio 1.47 1.27
69th		 3.02
Quick ratio 1.41 1.23
75th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.24 0.39
38th		 1.43
Defensive interval (days) 607 days 420 days
68th		 415 days

Leverage & solvency (latest quarter)

MeasureDVAIndustry medianIndustry percentileSector median
Total debt $10.8B $1.3B
94th		 $289.1M
Debt / equity —
Net debt / equity —
Debt / assets 60.9% 37.5%
84th		 24.4%
Debt / capital —
Debt / EBITDA 3.90 2.71
71st		 2.62
Net debt / EBITDA 3.65 2.19
75th		 1.42
Interest coverage (EBIT / interest) 3.7x 5.6x
33rd		 2.1x
Cash interest coverage 3.9x 9.7x
33rd		 3.6x
Debt payback (years of OCF) 4.9 yrs 3.7 yrs
66th		 2.7 yrs
Liabilities / assets 93.9% 61.0%
91st		 49.8%
IS credit model rating BB — —
Implied credit spread (bps) 475 225
78th		 225

Efficiency

MeasureDVAIndustry medianIndustry percentileSector median
Asset turnover 0.80 1.03
25th		 0.56
Fixed asset turnover 2.70 3.59
32nd		 4.87
Inventory turnover 64.9 35.3
67th		 2.7
Receivables turnover 5.7 8.8
9th		 6.4
Days sales outstanding 64 days 41 days
91st		 57 days
Days inventory outstanding 6 days 10 days
38th		 136 days
Days payables outstanding 25 days 21 days
53rd		 59 days
Cash conversion cycle (days) 45 days 22 days
91st		 70 days
Capex / revenue 4.2% 2.5%
68th		 2.6%
Capex / depreciation 0.82 0.83
48th		 0.55
Operating expense ratio 16.6% 16.0%
53rd		 56.5%

Cash flow & earnings quality

MeasureDVAIndustry medianIndustry percentileSector median
Operating cash flow / net income 2.59 1.64
78th		 1.61
FCF / net income 1.90 1.33
78th		 1.36
FCF / operating cash flow 73.4% 75.3%
46th		 81.2%
Capex / operating cash flow 26.6% 24.7%
54th		 18.8%
Accruals ratio -7.6% -6.3%
34th		 -5.4%
Sloan accruals ratio -3.0% -3.0%
50th		 -1.3%
Earnings quality score (0-1) 0.75 0.75
9th		 0.75

Dividends & buybacks

MeasureDVAIndustry medianIndustry percentileSector median
Dividend yield 0.0% 0.0%
0th		 0.0%
Dividend per share (TTM) $0.00 $0.00
0th		 $0.00
Payout ratio (dividends / net income) 17.7% 0.0%
91st		 0.0%
Dividends / FCF 9.3% 0.0%
77th		 0.0%
Dividend growth (YoY) —
Buyback yield 13.1% 0.8%
100th		 0.0%
Shareholder yield (dividends + buybacks) 14.3% 1.2%
100th		 0.0%
Share count change (YoY) -14.6% 0.6%
3rd		 2.0%
Buybacks, last 5 years $5.6B $60.6M
97th		 $0

Scores & forensic checks

MeasureDVAIndustry medianIndustry percentileSector median
IS score 44 57
31st		 46
IS profitability 30 32
41st		 22
IS growth 56 65
25th		 60
IS value 51 48
62nd		 39
IS momentum 75 85
38th		 67
IS risk (safety) 30 65
12th		 80
IS quality 64 61
59th		 49
IS balance sheet 27 50
16th		 55
IS earnings quality 63 72
34th		 56
IS cash flow 64 59
62nd		 41
Piotroski F-score (0-9) 8 6
78th		 5
Altman Z-score 1.8 2.7
16th		 3.2
Beneish M-score −2.81 −2.63
28th		 −2.62
Ohlson O-score −5.68 −7.12
84th		 −7.16
IS credit score 44 60
22nd		 62

Per share

MeasureDVAIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $12.82 $1.22
84th		 −$0.03
Book value per share −$11.58 $9.99
3rd		 $7.10
Tangible book per share −$104.05 $0.91
0th		 $1.91
Revenue per share $211.97 $36.86
88th		 $9.38
FCF per share $24.35 $2.23
91st		 $0.46
Operating cash flow per share $33.18 $2.62
91st		 $0.93
Cash per share $10.42 $1.87
88th		 $3.51

Size (TTM)

MeasureDVAIndustry medianIndustry percentileSector median
Market cap $12.0B $2.4B
91st		 $2.4B
Revenue $14.0B $2.6B
88th		 $770.2M
EBITDA $2.8B $303.8M
88th		 $56.1M
Net income $847.5M $104.9M
91st		 −$3.3M
Free cash flow $1.6B $165.8M
94th		 $41.2M
Total assets $17.7B $2.4B
94th		 $1.3B
Shareholders' equity −$765.1M $741.3M
6th		 $568.4M
Employees 78,000 15,278
91st		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-22Maughan David Paul
Chief Operating Officer, DKC
 Tax withholding 7,501$182.34$1.4M86,604
2026-08-15Hollar Jason M.
Director
 Award / grant 278——6,883
2026-08-15Desoer Barbara J
Director
 Award / grant 278——278
2026-08-15Schechter Adam H
Director
 Award / grant 278——5,970
2026-08-15Moore Gregory J.
Director
 Award / grant 278——8,091
2026-08-15Pullin Dennis W
Director
 Award / grant 278——2,949
2026-08-15Schoppert Wendy Lee
Director
 Award / grant 278——278
2026-08-15Arway Pamela M
Director
 Award / grant 278——27,223
2026-08-15Yale Phyllis R
Director
 Award / grant 278——9,803
2026-07-31Berkshire Hathaway Inc
10 percent owner
 Open-market sale 182,980$199.55$36.5M28,697,229
2026-06-16Rodriguez Javier
Director, Chief Executive Officer
 Open-market sale 39,407$209.28$8.2M840,408
2026-06-15Waters Kathleen Alyce
Chief Legal & Pub. Affairs Off
 Open-market sale 8,950$207.84$1.9M115,649

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarMayJunJulAugSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired164,224—
GiftDisposed15,038—
Open-market saleDisposed111,577,352$254.4M
Option exerciseAcquired15,784$639,884
Option exerciseDisposed15,784$639,884
Return to issuerDisposed13,231$640,061
Tax withholdingDisposed28,618$1.6M
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 8 notices · 173,996 shares · $34.9M
FiledFilerShares proposedEst. proceeds
2026-06-16Javier Rodgriguez39,407$8.2M
2026-06-15Waters Kathleen Alyce6,455$1.3M
2026-06-15Kathleen Waters8,950$1.9M
2026-06-15Javier Rodriguez30,000$6.3M
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 0 trades (0 purchases) · Senate 1 (1 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-03-27Alan ArmstrongSenatePurchase$1,001 - $15,0002026-07-20
2025-09-25Julie JohnsonHouseSale$1,001 - $15,0002025-10-08
2025-09-24Julie JohnsonHouseSale (Full)$1,001 - $15,0002025-10-08
2025-09-23Julie JohnsonHouseSale$1,001 - $15,0002026-08-06
2025-09-23Julie JohnsonHousePurchase$1,001 - $15,0002026-08-06
2023-12-14Jerry MoranSenateSale (Full)$1,001 - $15,0002024-01-17
2023-12-14Jerry MoranSenateSale (Full)$1,001 - $15,0002024-01-17
2023-12-14Jerry MoranSenateSale (Full)$1,001 - $15,0002024-01-16
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.2,460,987$547.5M3.86%
VANGUARD CAPITAL MANAGEMENT LLC2,101,425$467.5M3.29%
MORGAN STANLEY1,403,588$312.3M2.20%
VANGUARD PORTFOLIO MANAGEMENT LLC1,377,914$306.6M2.16%
STATE STREET CORP1,323,019$294.3M2.07%
Invesco Ltd.1,211,917$269.6M1.90%
DIMENSIONAL FUND ADVISORS LP1,137,814$253.1M1.78%
LSV ASSET MANAGEMENT908,389$202.1M1.42%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP889,082$197.8M1.39%
GEODE CAPITAL MANAGEMENT, LLC853,602$189.6M1.34%
Gates Capital Management, Inc.688,136$153.1M1.08%
BANK OF AMERICA CORP /DE/651,999$145.1M1.02%
D. E. Shaw & Co., Inc.640,827$142.6M1.00%
GOLDMAN SACHS GROUP INC463,381$103.1M0.73%
Bank of New York Mellon Corp451,040$100.3M0.71%

Institutional ownership by quarter

2023-092026-0691.7%
% of shares held by 13F filers
2023-092026-06630
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-3063091.7%12318722466
2026-03-3158195.8%13016621269
2025-12-31532102.6%80180201100
2025-09-30562103.8%7214026292
2025-06-30590108.7%6718623763
2025-03-31594110.0%8417923578
2024-12-31597113.7%8717224576
2024-09-30597115.1%9318422349
2024-06-30556117.6%8516621458
2024-03-31539120.1%7017020955
2023-12-31532122.0%8815020647
2023-09-30498122.3%7115718135

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2025-10-30SCHEDULE 13G/AThe Vanguard Group5.9%4,227,904
2025-04-25SCHEDULE 13G/ABlackRock, Inc.5.0%3,994,011
2025-02-13SCHEDULE 13D/ABerkshire Hathaway Inc.45.0%35,892,479
2025-02-13SCHEDULE 13D/AGEICO Corporation23.0%18,310,391
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
RSP0.20%$195.0M
VITSX0.01%$194.8M
VSMPX0.01%$194.8M
VTSAX0.01%$194.8M
VTI0.01%$194.8M
VFIAX0.01%$155.3M

Share structure

Shares outstanding63,800,000
Float62,476,086
Free float97.9%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$11.6B$11.6B$12.1B$12.8B$13.6B
Cost of revenue$8.0B$8.2B$8.3B$8.6B$10.0B
Gross profit$3.6B$3.4B$3.8B$4.2B$3.7B
R&D$0$0$0$0$0
SG&A$1.2B$1.4B$1.5B$1.5B$1.7B
Operating income$1.8B$1.3B$1.6B$2.1B$2.0B
EBITDA$2.5B$2.1B$2.3B$2.7B$2.6B
Pretax income$1.5B$966.3M$1.2B$1.5B$1.3B
Income tax$306.7M$198.1M$220.1M$279.7M$293.1M
Net income$978.5M$560.4M$691.5M$936.3M$746.8M
EPS, diluted$8.90$5.85$7.42$10.73$9.51
Diluted shares109.9M95.8M93.2M87.3M88.1M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$484.2M$321.8M$391.7M$846.0M$782.0M
Receivables$2.0B$2.3B$2.2B$2.6B$3.0B
Inventory$107.4M$109.1M$143.1M$134.6M$160.6M
Total current assets$3.2B$3.2B$3.1B$3.7B$4.1B
PP&E, net$6.3B$5.9B$5.6B$5.3B$5.2B
Goodwill & intangibles$7.2B$7.3B$7.3B$7.6B$7.8B
Total assets$17.1B$16.9B$16.9B$17.3B$17.5B
Accounts payable$402.0M$479.8M$514.5M$547.2M$696.1M
Total current liabilities$2.4B$2.6B$2.6B$3.0B$3.1B
Long-term debt$8.7B$8.7B$8.3B$9.2B$12.3B
Total liabilities$14.8B$14.7B$14.2B$15.2B$16.3B
Shareholders' equity$2.4B$2.2B$2.7B$2.1B$1.2B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$1.2B$781.6M$691.5M$1.3B$1.1B
Depreciation & amortization$680.6M$732.6M$745.4M$723.9M$715.3M
Stock-based compensation$102.2M$95.4M$112.4M$102.8M$140.0M
Change in working capital−$140.6M$101,000$194.5M−$29.8M−$263.2M
Operating cash flow$1.9B$1.6B$2.1B$2.0B$1.9B
Capital expenditure−$641.5M−$603.4M−$568.0M−$555.4M−$575.9M
Free cash flow$1.3B$961.1M$1.5B$1.5B$1.3B
Investing cash flow−$784.7M−$630.3M−$771.8M−$771.4M−$654.9M
Net debt issued / repaid$754.3M−$11.3M−$552.6M$1.1B$769.6M
Buybacks−$1.6B−$802.2M−$272.2M−$1.4B−$1.8B
Dividends paid$0$0$0$0$0

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin31.4%29.3%31.5%32.9%30.9%
Operating margin15.5%11.5%13.2%16.3%14.9%
Net margin8.4%4.8%5.7%7.3%5.5%
FCF margin11.1%8.3%12.3%11.4%9.6%
ROE91.5%76.4%78.2%159.1%-281.8%
ROIC11.7%8.7%11.1%15.1%11.7%
ROA5.7%3.3%4.1%5.5%4.3%
Debt / equity15.8516.6010.5399.63-23.12
Interest coverage6.3x3.7x4.0x4.3x3.5x
Current ratio1.321.201.191.261.29
Revenue growth+0.6%−0.1%+4.6%+5.6%+6.5%
EPS growth+39.9%−34.7%+22.2%+49.8%−24.1%
P/E at year end12.2x12.2x14.1x13.4x13.4x
EV / EBITDA at year end9.4x8.9x8.8x8.7x9.2x
FCF yield at year end10.81%14.00%15.36%11.69%13.09%
Dividend payout0.0%0.0%0.0%0.0%0.0%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
U S Dialysis And Related Lab Services$10.7B$10.6B$10.9B$11.3B$11.7B
Other Segments$1.0B$1.1B$1.3B——

Street estimates by fiscal year

Next report 2026-10-28 · consensus EPS $3.57 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$14.1B$14.0B – $14.3B$14.83$13.54 – $15.80512.6x
2027$14.5B$14.3B – $15.0B$16.96$16.73 – $17.10511.0x
2028$15.0B$14.3B – $15.9B$19.54$18.92 – $20.7139.6x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-08-04$3.88$4.02+3.6%$3.5B$3.6B+1.7%
2026-05-05$2.41$2.87+19.1%$3.4B$3.4B+1.8%
2026-02-02$3.24$3.40+4.9%$3.5B$3.6B+3.2%
2025-10-29$3.17$2.51−20.8%$3.4B$3.4B−0.2%
2025-08-05$2.70$2.95+9.3%$3.4B$3.4B−1.8%
2025-05-12$1.95$2.00+2.6%$3.2B$3.2B+0.5%
2025-02-13$2.14$2.24+4.7%$3.3B$3.3B+0.9%
2024-10-29$2.72$2.59−4.8%$3.3B$3.3B−0.1%
2024-08-06$2.54$2.50−1.6%$3.2B$3.2B+1.1%
2024-05-02$1.95$2.26+15.9%$3.0B$3.1B+1.4%
2024-02-13$1.59$1.62+1.9%$3.0B$3.1B+4.6%
2023-11-07$2.02$2.62+29.7%$3.0B$3.1B+3.4%
2023-08-03$1.69$1.91+13.0%$3.0B$3.0B+1.6%
2023-05-08$1.15$1.25+8.7%$2.8B$2.9B+1.2%
2023-02-22$0.88$1.11+26.1%$2.9B$2.9B−0.5%
2022-10-28$1.65$1.45−12.1%$3.0B$2.9B−1.0%
2022-08-01$2.09$2.30+10.0%$2.9B$2.9B−0.3%
2022-05-05$1.87$1.61−13.9%$2.9B$2.8B−2.5%
2022-02-10$1.80$2.02+12.2%$2.9B$2.9B+1.0%
2021-10-28$2.25$2.36+4.9%$2.9B$2.9B+0.5%
2021-08-03$2.17$2.64+21.7%$2.9B$2.9B+1.6%
2021-04-29$1.82$2.09+14.8%$2.8B$2.8B−0.2%
2021-02-11$1.87$1.67−10.7%$2.9B$2.9B−0.8%
2020-10-29$1.49$1.80+20.8%$2.3B$2.9B+25.0%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.206-150.206-220.206-290.307-060.207-130.207-200.207-270.608-030.208-100.108-170.208-240.108-31
Week ofNotionalSharesTrades
2026-08-31$135.0M751,16631,153
2026-08-24$154.9M871,50534,532
2026-08-17$110.2M624,08331,998
2026-08-10$200.3M1,105,93641,167
2026-08-03$587.2M2,889,78864,603
2026-07-27$194.6M811,99534,515

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1562.3%
DateShort shareShort volumeTotal volume
2026-10-1562.3%141,166226,645
2026-10-1475.8%95,210125,634
2026-10-1360.2%84,144139,679
2026-10-1272.4%86,815119,831
2026-10-0967.4%85,471126,882
2026-10-0868.6%121,760177,555
2026-10-0772.0%186,129258,583
2026-10-0658.0%73,968127,603
2026-10-0560.5%91,127150,736
2026-10-0270.1%122,064174,124
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+2.2Jan+1.5Feb+0.8Mar+1.5Apr-1.4May+1.5Jun-0.3Jul+0.6Aug+0.2Sep-2.1Oct+4.8Nov+0.7Dec
MonthAvg returnUp yearsYears
Jan+2.2%55%20
Feb+1.5%50%20
Mar+0.8%48%21
Apr+1.5%55%20
May−1.4%50%20
Jun+1.5%50%20
Jul−0.3%50%20
Aug+0.6%50%20
Sep+0.2%50%20
Oct−2.1%50%20
Nov+4.8%60%20
Dec+0.7%50%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1457.6
MFI68.5
ADX14.8
Stochastic %K / %D82.9 / 78.7
Williams %R-16.3
CCI174
TSI / signal0.2 / -9.0
Chaikin money flow-0.24
ATR$4.67
Bollinger width8.5%
Volume vs 20-day avg0.94x
SupertrendDown

Moving averages and bands

level (price vs level)
SMA 20$179.94 (+4.1%)
SMA 50$180.49 (+3.8%)
SMA 200$173.37 (+8.0%)
EMA 21$181.69 (+3.1%)
EMA 50$185.59 (+0.9%)
EMA 200$177.11 (+5.8%)
Bollinger upper$187.61 (−0.2%)
Bollinger lower$172.26 (+8.7%)
Parabolic SAR$175.43 (+6.8%)
Open the live chart, 110+ indicators

About DaVita Inc.

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

https://www.davita.com

Key executives

NameTitlePayBorn
Javier J. RodriguezChief Executive Officer & Executive Director$4.1M1971
David MaughanChief Operating Officer of DaVita Kidney Care$1.7M1977
Joel AckermanChief Financial Officer & Treasurer$1.6M1965
Kathleen Alyce WatersChief Legal & Public Affairs Officer$1.4M1968
James O. HeartyChief Compliance Officer$1.1M1969
Christopher Michael BerryGroup Vice President & Chief Accounting Officer—1975
Jeffrey Allen GiullianChief Medical Officer of Kidney Care——
Misha PalecekChief Transformation Officer of U.S. Kidney Care Business——

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Javier J. Rodriguez Chief Executive Officer2025$1.5M$11.4M$2.1M$18.2M
Joel Ackerman Chief Financial Officer and Treasurer2025$834,616$3.6M$774,063$6.1M
David P. Maughan Chief Operating Officer, DaVita Kidney Care2025$725,000$3.2M$686,330$5.6M
Kathleen A. Waters Chief Legal and Public Affairs Officer2025$750,000$2.0M$662,664$3.9M
James O. Hearty Chief Compliance Officer2025$600,000$720,420$455,331$2.0M

Employees

78k201865k201967k202069k202170k202270k202376k202478k2025

Dividends

Ex-dateAmountPaid
None on file.

Moat model

Weak · Cost Advantage · 2026-06-30
Cost advantage71
Intangibles44
Switching costs27
Network effect40
Efficient scale56
Our component scores (0-100) and overall 46.4; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms